# AstraZeneca Lynparza granted orphan drug designation in Japan

- Link: https://www.directorstalkinterviews.com/astrazeneca-lynparza-granted-orphan-drug-designation-in-japan/412809229
- Published: 2020-03-19T08:05:30+00:00
- Author: Amilia Stone

**[AstraZeneca plc](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)**(
[LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
today announced that _Lynparza_ (olaparib) has been granted orphan drug designation(
ODD) in Japan for the maintenance treatment of germline BRCA-mutated (gBRCAm) curatively
unresectable pancreatic cancer. _Lynparza_ is co-developed and co-commercialised
with MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the 
US and Canada).

The Japanese Ministry of Health, Labour and Welfare grants ODD to medicines intended
for the treatment of diseases that affect fewer than 50,000 patients in Japan and
for which there is a high unmet medical need.

Pancreatic cancer has the lowest survival rate of the most common cancers and is
the only major cancer with a five-year survival rate below 10% in almost every country.

> **José Baselga, Executive Vice President, R&D Oncology, said**: “Japan has the
> fifth-highest incidence of pancreatic cancer worldwide and patients have seen 
> limited treatment advances over the last few decades. This designation is an important
> step forward in bringing the first targeted medicine to biomarker-selected patients
> with advanced pancreatic cancer in Japan.”

> **Roy Baynes, Senior Vice President and Head of Global Clinical Development, Chief
> Medical Officer, MSD Research Laboratories, said**: “A pancreatic cancer diagnosis
> is devastating and we are committed to research that aims to change the prognosis
> for patients. The POLO trial demonstrated that treatment with _Lynparza_ extended
> time without disease progression or death in patients with germline BRCA-mutated
> metastatic pancreatic cancer and we are hopeful that we will be able to bring 
> this treatment to patients in Japan soon.”

The Phase III POLO trial showed _Lynparza_ nearly doubled the time patients with
gBRCAm metastatic pancreatic cancer lived without disease progression or death to
a median of 7.4 months versus 3.8 months on placebo. The safety and tolerability
profile of _Lynparza_ in the POLO trial was in line with that observed in previous
trials.

_Lynparza_ was approved in the US as a 1st-line maintenance treatment for patients
with gBRCAm metastatic pancreatic cancer in December 2019 with ongoing regulatory
reviews in the EU and other jurisdictions.

**Pancreatic cancer**

Pancreatic cancer is a deadly cancer with a high unmet medical need. The disease
has the lowest survival rate of the most common cancers.^(1) Japan has the fifth-
highest rate of pancreatic cancer in the world with 43,000 new cases diagnosed in
2018.^(2,3) Pancreatic cancer is the fourth leading cause of cancer death in Japan,
resulting in 37,000 deaths in 2018.^(3)

Globally, pancreatic cancer is the 11th-most commonly occurring cancer^( )and the
seventh leading cause of cancer death.^(4,5) There were approximately 460,000 new
cases worldwide in 2018.^(5) As there are often no symptoms, or symptoms may be 
non-specific in the early stages, it is most commonly diagnosed at an incurable 
stage.^(6,7) Around 80% of pancreatic cancer patients are diagnosed when the disease
has metastasised, at which point average survival is less than a year.^(8) Despite
advances in treatment, few improvements have been made in diagnosis and treatment
in the past few decades.^(9) Current treatment is surgery (for which approximately
only 10-20% of patients are eligible), chemotherapy and radiotherapy, highlighting
a critical unmet medical need for more effective treatment options.^(10)

**POLO**

POLO is a Phase III randomised, double-blind, placebo-controlled, multi-centre trial
of _Lynparza_ tablets (300mg twice daily) as maintenance monotherapy versus placebo.
The trial randomised 154 patients with gBRCAm metastatic pancreatic cancer whose
disease had not progressed on 1st-line platinum-based chemotherapy. Patients were
randomised (3:2) to receive _Lynparza_ or placebo until disease progression. The
primary endpoint was progression-free survival (PFS) and key secondary endpoints
included overall survival (OS), time to second disease progression, overall response
rate and health-related quality of life.

The results showed a statistically significant and clinically meaningful improvement
in PFS, where _Lynparza_ nearly doubled the time patients with gBRCAm metastatic
pancreatic cancer lived without disease progression or death to a median of 7.4 
months versus 3.8 months on placebo and reduced the risk of disease progression 
or death by 47% (HR 0.53 [95% confidence interval (CI), 0.35-0.82], p=0.004). In
patients with measurable disease at baseline, 23% responded to _Lynparza_ versus
12% on placebo (odds ratio, 2.30 [95% CI, 0.89-6.76]) and had a median duration 
of treatment in excess of two years (24.9 months [95% CI, 14.8-could not be calculated])
versus 3.7 months on placebo (95% CI, 2.10-could not be calculated). The median 
OS, a secondary endpoint, at interim analysis and at a data maturity of 46% was 
18.9 months for _Lynparza_ versus 18.1 months for placebo but did not reach statistical
significance (HR=0.91; p=0.68).

The safety and tolerability profile of _Lynparza_ in the POLO trial was in line 
with that observed in previous trials.

**BRCA mutations**

BRCA1 and BRCA2 (breast cancer susceptibility genes 1/2) are human genes that produce
proteins responsible for repairing damaged DNA and play an important role in maintaining
the genetic stability of cells. When either of these genes is mutated, or altered,
such that its protein product either is not made or does not function correctly,
DNA damage may not be repaired properly, and cells become unstable. As a result,
cells are more likely to develop additional genetic alterations that can lead to
cancer.

**Lynparza**

_Lynparza_ (olaparib) is a first-in-class PARP inhibitor and the first targeted 
treatment to block DNA damage response (DDR) in cells/tumours harbouring a deficiency
in homologous recombination repair, such as mutations in BRCA1 and/or BRCA2. Inhibition
of PARP with _Lynparza_ leads to the trapping of PARP bound to DNA single-strand
breaks, stalling of replication forks, their collapse and the generation of DNA 
double-strand breaks and cancer cell death. _Lynparza_ is being tested in a range
of PARP-dependent tumour types with defects and dependencies in the DDR pathway.

_Lynparza_ is currently approved in a number of countries, including those in the
EU, for the maintenance treatment of platinum-sensitive relapsed ovarian cancer.
It is approved in the US, the EU, Japan, China, and several other countries as 1st-
line maintenance treatment of BRCA-mutated advanced ovarian cancer following response
to platinum-based chemotherapy. It is also approved in the US, Japan, and a number
of other countries for germline BRCA-mutated, HER2-negative, metastatic breast cancer,
previously treated with chemotherapy; in the EU, this includes locally advanced 
breast cancer. In 2019, _Lynparza_ was additionally approved in the US for the treatment
of germline BRCA-mutated metastatic pancreatic cancer. Regulatory reviews are underway
in several jurisdictions for ovarian, breast, pancreatic and prostate cancers.

_Lynparza_, which is being jointly developed and commercialised by AstraZeneca and
MSD, has been used to treat over 30,000 patients worldwide. _Lynparza_ has the broadest
and most advanced clinical trial development programme of any PARP inhibitor, and
AstraZeneca and MSD are working together to understand how it may affect multiple
PARP-dependent tumours as a monotherapy and in combination across multiple cancer
types. _Lynparza_ is the foundation of AstraZeneca’s industry-leading portfolio 
of potential new medicines targeting DDR mechanisms in cancer cells.

Share on:
